Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, has recently been featured in an editorial by NetworkNewsWire, spotlighting its groundbreaking precision genetic medicine platform. This platform is designed to target both primary and metastatic cancer tumors through the use of engineered viruses, presenting a promising avenue in the fight against cancer. With projections indicating that global cancer diagnoses could soar to 35 million annually by 2050, Calidi's technology is timely, addressing a critical unmet need in oncology.
The company's innovative approach involves delivering potent genetic therapies directly to cancer sites, leveraging engineered viruses to attack tumors. This method not only aims to enhance the efficacy of cancer treatments but also seeks to improve patient safety by minimizing the side effects associated with traditional therapies. Calidi's platform is built on proprietary stem cell-based technologies that utilize allogeneic stem cells to carry oncolytic viruses, targeting high-grade gliomas and solid tumors among other indications.
Calidi Biotherapeutics is at the forefront of developing off-the-shelf, universal cell-based delivery platforms that protect, amplify, and potentiate oncolytic viruses. Additionally, the company is advancing preclinical enveloped virotherapies aimed at disseminated solid tumors, offering a dual approach that could potentially treat or prevent metastatic disease. Headquartered in San Diego, California, Calidi is pioneering a new frontier in cancer treatment, with its technologies holding the promise of transforming the therapeutic landscape for patients worldwide.
For more information on Calidi Biotherapeutics and its innovative cancer treatment platforms, visit https://www.calidibio.com. Investors seeking the latest updates on CLDI can find more information in the company's newsroom at https://ibn.fm/CLDI.
